PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ATORVASTATIN AND RELATED SPECIES AND PREDICTION OF DRUG-DRUG INTERACTIONS IN HUMANS.

被引：0
|
作者：
Morse, B. L. [1 ]
Alberts, J. J. [1 ]
Kolur, A. [1 ]
Posada, M. M. [1 ]
Tham, L. [1 ]
Loghin, C. [1 ]
Hall, S. D. [1 ]
Dickinson, G. L. [1 ]
Hillgren, K. M. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-077
引用
收藏
页码：S63 / S64
页数：2
相关论文
共 50 条
  • [31] Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat
    Frechen, Sebastian
    Ince, Ibrahim
    Dallmann, Andre
    Gerisch, Michael
    Jungmann, Natalia A.
    Becker, Corina
    Lobmeyer, Maximilian
    Trujillo, Maria E.
    Xu, Shiyao
    Burghaus, Rolf
    Meyer, Michaela
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (01): : 79 - 92
  • [32] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [33] Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions
    Chen, Yuan
    Ma, Fang
    Jones, Nicholas S.
    Yoshida, Kenta
    Chiang, Po-Chang
    Durk, Matthew R.
    Wright, Matthew R.
    Jin, Jin Yan
    Chinn, Leslie W.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 332 - 341
  • [34] Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions
    Ono, Chiho
    Hsyu, Poe-Hirr
    Abbas, Richat
    Loi, Cho-Ming
    Yamazaki, Shinji
    [J]. DRUG METABOLISM AND DISPOSITION, 2017, 45 (04) : 390 - 398
  • [35] Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions
    Rytkonen, Jaana
    Ranta, Veli-Pekka
    Kokki, Merja
    Kokki, Hannu
    Hautajarvi, Heidi
    Rinne, Valtteri
    Heikkinen, Aki T.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2020, 41 (1-2) : 72 - 88
  • [36] Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation
    Hsueh, Chia-Hsiang
    Hsu, Vicky
    Pan, Yuzhuo
    Zhao, Ping
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (10) : 1337 - 1346
  • [37] Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software
    Marsousi, Niloufar
    Desmeules, Jules A.
    Rudaz, Serge
    Daali, Youssef
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (01) : 3 - 17
  • [38] Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential
    Patel, Nikunjkumar K.
    Chen, Kuan-Fu
    Chen, Shang-Chiung
    Liu, Kai
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (02): : 317 - 329
  • [39] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex
    Conner, Todd M.
    Nikolian, Vahagn C.
    Georgoff, Patrick E.
    Pai, Manjunath P.
    Alam, Hasan B.
    Sun, Duxin
    Reed, Ronald C.
    Zhang, Tao
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 111 : 465 - 481
  • [40] Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer
    Morita, Tomoko O.
    Hanada, Kazuhiko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (04) : 315 - 323
12345